Summary:
CinDome Pharma, Inc. (hereafter CinDome Pharma) is developing CIN-102, a deuterated form of domperidone, for the management and relief of symptoms associated with gastroparesis. This is a Phase 2 study to evaluate the efficacy and safety of CIN-102 in adult subjects with diabetic gastroparesis.
Criteria:Must be 18 years of age and above
Has a diagnosis of Type 1 or Type 2 diabetes
Has documented delayed gastric emptying test
Qualified Participants May Receive:
Will recieve compensation after each completed visit.